News Pfizer builds on Braftovi bowel cancer OK with survival data Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Rad AI raises $60m, and other digital financings Recent financings in the digital health and AI space include rounds for Rad AI, Eleos, Allara Health, Manas AI, Delfina Care, and Grey Matter Neuro.
News Could an ECG spot people at risk of cognitive decline? UK Biobank study suggests someone's risk of premature ageing or cognitive decline could be predicted using a simple ECG reading supported by an AI.
News Takeda CEO succession confirmed as Weber plans retirement Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.
News Troubled 23andMe is exploring a sale of the business Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.
News Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.